Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect on PK/PD of HIP1601 in Healthy Volunteers
NCT04204629Phase 1Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- Jan 2020
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of esomeprazole strontium in gastroesophageal reflux disease (GERD) and erosive esophagitis (EE) (2 arms), sponsored by Hanmi Pharmaceutical. Primary endpoints: Maximum Plasma Concentration at 24 hours, Area Under the Curve to the last measurable concentration at 24 hours and 1 more. Started Jan 2020; status: completed.
02
Drugs
esomeprazole strontium
03
Conditions
gastroesophageal reflux disease (GERD)erosive esophagitis (EE)
Beyond the preview
Go deeper on NCT04204629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04204629.